The statins have emerged as the dominant class of drug for the treatment of hypercholesterolemia. These medications are generally well tolerated. However, myalgias, the most frequent side-effect, occur in up to 7% of patients. 1 Transaminitis and skeletal myotoxicity, with elevated serum creatine kinase (CK) levels (i.e., >10 times the upper limit of normal), occur with reported frequencies of 1% and 0.1%, respectively. 2 Various hypotheses have been proposed to explain the relationship between statin therapy and the spectrum of muscle dysfunction manifested by myalgia, myopathy, and rhabdomyolysis.
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Statin-mediated inhibition of mevalonate metabolism impairs the synthesis of isoprenylated products−the most notable of which is ubiquinone. However, isoprenylation is responsible for the post-translational modification of up to 2% of cellular proteins. 3 Therefore, numerous metabolic pathways are potentially modified by statin-mediated hypoprenylation. Subclinical defects in one or more energy-deriving pathways may be unmasked upon exposure to the pleotropic effects of statins. Such pharmacogenomic synergism may underlie the development of "statin myopathy" in a subset of patients. In this regard, we describe four patients with mutations in the myophosphorylase (PYGM; MIM 232600), myoadenylate deaminase (AMPD1; MIM 102770), and carnitine palmitoyltransferase (CPT2; MIM 600650) genes whose diagnoses became apparent during the course of investigations for statin-induced myalgias and hyperCKemia.
CASE REPORTS
Patient A, a 70-year-old Italian male, was found to have a high CK activity (416 U/L) on routine blood work approximately one year following initiation of cerivastatin. A repeat CK measured 1516 U/L and the statin was discontinued after which the CK dropped to 287 U/L five months later. Over the next eight months his CK remained elevated with the nadir of 488 U/L. He consistently reported proximal muscle aches with slight weakness on stair climbing and easy fatigability with moderate intensity activities. These symptoms were exaggerated during statin exposure and improved after discontinuation of the statin and coincident coenzyme Q10 supplementation (60 mg twice daily). Neurologic examination was normal. Specifically, there was no evidence of ptosis, ophthalmoparesis, dysphagia, or neck extensor weakness. Muscle stretch reflexes and sensation were intact. He manifested mild hip flexor weakness. Nerve conduction studies and electromyography (EMG) were normal. Ergometry and forearm ischemic testing were not performed. [4] .
Metabolic Myopathies Discovered During Investigations of Statin Myopathy
Patient B, a 53-year-old athletic man with a history of essential hypertension and familial hypercholesterolemia, reported exercise intolerance, exertional cramps, and fatigue three months after initiating atorvastatin therapy (20 mg). The initial CK was elevated at 2,990 U/L and subsequently declined to normal several weeks after discontinuation. Symptoms persisted and he experienced mild CK elevations in response to day-surgery and E. Coli gastroenteritis.
There was no family history of neuromuscular disease and his physical examination was normal. Screening blood work revealed normal values for the following: erythrocyte sedimentation rate, complete blood count, electrolytes, lactate, pyruvate, homocysteine, anti-nuclear antibody, and carnitine levels (free, esterified, and total). Electrophysiologic studies demonstrated normal sensory and motor nerve function. Subtle small brief early recruiting motor unit action potentials were observed in proximal muscles on needle electromyography. Biopsy of the right vastus lateralis revealed mild variability in fiber size and rare ring fibers. There was dense uptake of oxidative enzymes in the subsarcolemmal space of several fibers. Electron microscopy demonstrated marked mitochondrial proliferation and numerous paracrystalline inclusions. Biochemical analyses of intramuscular carnitine, myoadenylate deaminase, carnitine palmitoyltransferase (CPT) II, myophosphorylase, and mitochondrial oxidative enzymes were normal. Mutation analysis demonstrated heterozygosity for the R50X mutation in exon 1 of the PYGM gene at chromosome 11q13. Carrier status for McArdle disease was confirmed in leukocytederived DNA [4] .
Patient C, a 58-year-old male, was noted to have asymptomatic hyperCKemia (1,045 U/L) on routine surveillance two months after starting atorvastatin (20 mg). His baseline CK was 266 U/L (N < 220 U/L). The atorvastatin was discontinued and his CK renormalized. Ezetimibe was trialed with no adverse effects. After approximately ten months of therapy his CK was found to be significantly elevated at 4,448 U/L. His CK normalized to 225 U/L within three weeks while remaining on ezetimibe. Similar monophasic rises were noted on two further occasions (i.e., 991 → 289 U/L and 1512 → 251 U/L). These fluctuations corresponded to sporadic exercise training.
Neurologic examination did not demonstrate ptosis, ophthalmoparesis, dyphagia, nor sensorimotor deficit. Muscle stretch reflexes, balance, and coordination were normal. Exercise intolerance was not documented on clinical history and therefore exercise testing was not performed. Nerve conduction studies were normal. Needle EMG in selected lower extremity muscles was unremarkable. A needle biopsy of m. vastus lateralis revealed normal fiber size/shape variability associated with mild nuclear internalization. There was no inflammatory infiltrate or vasculitis. Adenosine triphosphatase staining revealed normal type 1 and 2 fibers without grouping or type atrophy. Histochemical staining for myophosphorylase activity was normally reactive whereas myoadenylate deaminase was nonreactive. Staining for cytochrome oxidase, succinate dehydrogenase, Gomori trichrome, periodic acid Schiff, and Oil Red O revealed normal staining patterns. Electron microscopy showed normal sarcoplasmic Z-band architecture. There was no subsarcolemmal, intermyofibrillary nor vacuolar glycogen accumulation. In light of the staining abnormality, screening for potential subclinical molecular defects, in the three most common genes responsible for metabolic myopathies, was undertaken. 4 Homozygous mutations in the common cosegregating tandem mutations, Q12X and P48L, were identified in AMPD1 confirming myoadenylate deaminase deficiency.
Patient D, a 65-year-old male, was placed on pravastatin (40 mg) after 3-vessel coronary artery bypass grafting. Within six months he developed lower extremity cramping, myalgia, and fatigue. The finding of moderate CK elevation prompted a switch to simvastatin (20 mg) without symptom resolution. Although initially normal (212 U/L) his CK rose to 980 U/L after an additional six month interval. A trial of rosuvastatin (20 mg) perpetuated his myalgias and cramping even with alternate day dosing. His CK remained elevated at 598 U/L. Finally, ezetimibe (10 mg) replaced rosuvastatin, the CK normalized to 138 U/L, and his symptoms improved.
Neurologic examination was within normal limits showing no evidence of craniobulbar, peripheral nerve or muscle dysfunction. A limited needle EMG showed occasional fibrillations and positive sharp waves in the left tibialis anterior. A needle biopsy of m. vastus lateralis revealed no abnormalities. Direct sequencing of the CPT2 gene demonstrated a single defective allele harboring an F352C mutation.
DISCUSSION
Statin myopathies are a heterogeneous group of disorders ranging from trivial myalgias to rhabdomyolysis. Multiple mechanisms presumably account for this phenotypic diversity. While clues to the pathogenesis of statin myopathy have recently emerged with the reports of polymorphisms in a variety of genes including CYP2D6, 5 OAT3, 6 COQ2, 7 and serotonin receptors (3B and 7) 8 our knowledge gap remains substantial. Calcium dysregulation has been implicated in myotoxicity as statins (1) increase cytoplasmic and sarcoplasmic reticulum (SR) calcium levels, 9 (2) regulate SR-calcium-adenosine triphosphatase expression, 10 and (3) induce calcium-dependent mitochondrial permeability transition pore formation. 11 Eccentric exercise upregulates components of the ubiquitin-proteosome pathway in statin-exposed muscle but this mechanism fails to explain symptoms in sedentary patients. G-protein hypoprenylation may be an important mechanism of statin toxicity as both farensylated Ras 12 and geranylgeranylated Rab 13 have been implicated in the development of myopathy.
It has been previously suggested that latent mitochondrial dysfunction renders muscle more vulnerable to the coenzyme Q10 (ubiquinone) depleting potential of statin therapy. 14 This notion is supported by reports of statins triggering a mitochondrial, encephalomyopathy, lactic acidosis stroke-like epidsodes (MELAS) syndrome in two patients 15, 16 and lactic acidosis in another. 17 There is biochemical rationale for statinmediated cellular energy dysfunction as inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterol biosynthetic pathway lowers mevalonate and its distal isoprenoid metabolites including ubiquinone. The redox activity of ubiquinone's quinoid moiety is critically dependent on the ten isoprenoid tail units, which confers mobility within the hydrophobic inner mitochondrial membrane enabling electron shuttling in the respiratory chain. Indeed, cases A and B manifested paracrystalline inclusions which represent the crystallized form of dimeric mitochondrial creatine kinase under conditions of oxidative stress. However, this often cited mechanism may be overly simplistic given the report of ezetimibe-induced rhabdomyolysis in a sedentary patient with McArdle disease. 18 Ezetimibe inhibits the intestinal cholesterol transporter Niemann-Pick C1-Like 1 protein and has no known effect on isoprenoid synthesis. 19 In contrast to a previous report of complete reversal of a statin myopathy after coenzyme Q10 therapy, 20 patient A had a noticeable but incomplete response and continued to manifest hyperCKemia secondary to genetically confirmed McArdle disease. The finding of statin myopathies in patients harboring single mutant alleles in genes encoding either myophosphorylase and CPT II suggests that sub-clinical inborn errors of metabolism may be permissive in the development of myotoxic reactions. Similarly, a more benign metabolic defect of muscle− myoadenylate deaminase deficiency may be susceptible to statins only in the homozygous state. 4 We have recently found that mutant alleles for McArdle disease (incidence:
1/110,000 21 ) and CPTII deficiency (incidence:~1/291,000 4 ) were respectively 20-and 11-fold more likely in statin intolerant patients than expected in the general population. 4 The current case series permits speculation regarding the theory that inborn derangements of intermediary metabolism (i.e., glycolysis, β-oxidation, or purine nucleotide cycle) may render skeletal muscle more vulnerable to statin-mediated diminution of intramuscular coenzyme Q 10 levels and metabolic activity. This "multiple pathway synergy" hypothesis is reinforced by the reports of combined partial deficiencies of CPT II and mitochondrial complex I causing hyperCKemia 22 and valproic acid unmasking a MELAS syndrome (i.e., fatty acid oxidation + oxidative phosphorylation). 23 A report of statin therapy producing symptomatic exacerbation in a patient with CPT II deficiency provides further support of multiple pathway interdependence. 24 Preliminary evidence of statin-mediated reductions in L-carnitine suggests that a pharmacogenomic disruption of a single pathway may be pathogenic. 4, 25, 26 Furthermore, statins impair mitochondrial respiration and reduce rates of β-oxidation and levels of intracellular long-chain fatty acids. 27, 28 These effects may be mediated through activation of peroxisome proliferator-activated receptors (PPAR) α and γ. 28 The fibrates also activate PPARα and augment fatty acid metabolism. The combined influence on the PPAR system by statins and fibrates may offer a potential mechanism to explain their additive myotoxicity. Interestingly, fibrates have recently been shown to reduce mitochondrial complex I activity by approximately 20% offering another level of interaction between these two drug classes. 29 Thus the multiple pathway synergy model serves as a mechanism for both drug-drug and drug-gene interactions. These cases reflect an emerging complexity in the diagnosis of statin myopathy and highlight the need for baseline CK measurement even though biopsy-proven myopathy can develop in the absence of CK perturbations. 30 The pleotropic metabolic effects of statins may be reflected in the broad spectrum of clinically and genetically diverse neuromuscular disorders that may be potentially unmasked upon statin exposure (Table) . It is important to obtain a thorough neuromuscular history to determine if statin therapy may have unmasked a metabolic myopathy. However, searching for carriers of recessive inborn errors of metabolism, in statin intolerant patients, cannot be widely endorsed at this point and further work is needed to clarify a rational work-up of these patients.
